

## Curriculum Vitae

Personal information **Milou-Daniel Drici**

### Work experience

---

1. Employer: Cote d'Azur University Medical Center
  - Start date: 2003
  - End date:
  - Position: Chief of Department and Chair, Pharmacology
  - Activities: Director of the Regional Pharmacovigilance Center of Nice\_Alpes\_Cote d'Azur  
Chief of Department of Pharmacology (Therapeutic Drug Monitoring; Medical Toxicology)
  - Country: France
2. Employer: University of Nice
  - Start date: 2003
  - End date:
  - Position: Professor of Clinical Pharmacology
  - Activities: Therapeutic Drug Monitoring Clinical Trials
  - Country: France
3. Employer: Nice University Medical Center\_ Health Regional Agency
  - Start date: 2010
  - End date:
  - Position: Director of the Regional Pharmacovigilance Center of Nice\_Alpes\_Côte d'Azur (2.3 millions inhabitants)
  - Activities:
  - Country: France
4. European Medicines Agency
  - Start date: 072019
  - End date:
  - Position: PRAC independent scientific expert (for the EC)
  - Activities:
  - Country: Netherlands
5. Employer: AZCERT Inc
  - Start date: 2015
  - End date:
  - Position: Board Member of Credible Meds for QT drugs/DTA lists
  - Activities: Provide independent advice on drug safety in the domain of Congenital Long QT Syndrome
  - Country: United States
6. European Medicines Agency
  - Start date: 2010
  - End date: september 2020
  - Position: Co\_opted Member of the SAG Cardio
  - Activities: Provide independent advice on cardiovascular drug safety
  - Country: United Kingdom
7. Employer: French national agency of drug safety ANSM
  - Start date: 2000
  - End date:
  - Position: External Expert (CNS, cancer, AB and antiviral drugs)
  - Activities:
  - Country: France
8. Employer: French national agency of drug safety ANSM
  - Start date: 2018
  - End date:
  - Position: ASNM Working Groups member : CSP Member Cardiology & Pharmacovigilance
  - Activities:
  - Country: France
9. Employer: IUPHAR
  - Start date: 072013
  - End date: 072018
  - Position: President, IUPHAR Subcommittee of Pharmacovigilance\_Pharmacoepidemiology
  - Activities:
  - Country: United States
10. Employer: University of Nice
  - Start date: 1993
  - End date: 2003
  - Position: Associate Professor of Clinical Pharmacology
  - Activities:
  - Country: France
11. Employer: University of Nice School of Medicine
  - Start date: 1989
  - End date: 1993
  - Position: Assistant Professor in Clinical Pharmacology
  - Activities:
  - Country: France
12. Employer: Nice and Paris University Hospitals
  - Start date: 1982
  - End date: 1989
  - Position: Resident in Cardiology and Clinical Pharmacology

- Activities:
- Country: France

## Education and training

1. Subject: KJ Rothman & EE Hatch \_ Faculty of Medicine A. Gemelli
  - Start date: 112013
  - End date: 112013
  - Qualification: Epidemiologic Principles and Methods
  - Organisation:
  - Country: Italy
2. Subject: Georgetown University
  - Start date: 011995
  - End date: 041997
  - Qualification: International Merck Fellowship in Clinical Pharmacology (laureate)
  - Organisation:
  - Country: United States
3. Subject: University of Aix\_Marseille School of Pharmacy
  - Start date: 1993
  - End date:
  - Qualification: Ph. D. in Clinical Pharmacology
  - Organisation:
  - Country: France
4. Subject:
  - Start date: 1989
  - End date:
  - Qualification: Cardiology and Vascular Diseases board certification
  - Organisation:
  - Country:
5. Subject: University of Nice
  - Start date: 1989
  - End date:
  - Qualification: M.D.
  - Organisation:
  - Country: France
6. Subject: Food and Drugs Administration
  - Start date: 011995
  - End date: 041997
  - Qualification: Internal Reviewing Courses : Topics in Clinical Trials \_ Clinical Pharmacokinetics \_ Basic Statistical Methods \_
  - Organisation: Complex issues of Clinical Trials Clinical Pharmacokinetics Basic statistics of epidemiological datas
  - Country: United States

## Additional information

### Publications

Recent bibliography : • Gérard AO, Merino D, Drici MD. Real\_World Data on the Risk of Ventricular Arrhythmias with Sulfonamides. Clin Pharmacol Ther. 2022 Aug;112(2):201\_202. • Merino D, Gérard AO, Thümmel S, Ben Othman N, Viard D, Rocher F, Destere A, Van Obberghen EK, Drici MD. Drug-Associated Parosmia: New Perspectives from the WHO Safety Database. J Clin Med. 2022 Aug 9;11(16):4641. • Medications as a Trigger of Sleep-Related Eating Disorder: A Disproportionality Analysis. Merino D, Gérard AO, Van Obberghen EK, Ben Othman N, Ettore E, Giordana B, Viard D, Rocher F, Destere A, Benoit M, Drici MD. J Clin Med. 2022 Jul 4;11(13):3890. • Activation of the Tubulo-Glomerular Feedback by SGLT2 Inhibitors in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease: Toward the End of a Myth? Gérard AO, Laurain A, Favre G, Drici MD, Esnault VLM. Diabetes Care. 2022 Oct 1;45(10):e148\_e149. • Merino D, Gérard AO, Van Obberghen EK, Ben Othman N, Ettore E, Giordana B, Viard D, Rocher F, Destere A, Benoit M, Drici MD. COVID\_19 vaccine-associated transient global amnesia : a disproportionality analysis of the WHO safety database. Front Pharmacol. 2022 May 20;13:909412. • Alunni V, Bernardi C, Chevalier N, Cabusac C, Quatrehomme G, Torrents J, Biglia E, Gaillard Y, Drici MD. Postmortem PF4 antibodies confirm a rare case of thrombosis thrombocytopenia syndrome associated with XChAdOx1nCoV\_19 antiCOVID vaccination. Int J Legal Med. 2022 Oct 27;1\_6. doi: 10.1007/s00414\_022\_02910\_1. Online ahead of print. PMID: 36289074 • Gérard AO, Barbosa S, Parassol N, Andreani M, Merino D, Cremoni M, Laurain A, Pinel S, Bourneau\_Martin D, Rocher F, Esnault VLM, Borchellini D, Sicard A, Drici MD. Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events : a case-control study. Clin Kidney J. 2022 Apr 28;15(10):1881\_1887. • Romani S, Fresse A, Parassol\_Girard N, Gerard A, Levraut M, Yamani S, Van Obberghen EK, Pariente A, Rocher F, Viard D, Drici MD. Spontaneous reporting of adverse drug reactions as an outlet for patient dismay? The case of Levthyrox® change of excipients. Fundam Clin Pharmacol.2022;36(3):553\_562. • Gérard AO, Merino D, Van Obberghen EK, Rocher F, Destere A, Lantéri\_Minet M, Drici MD. Calcitonin gene-related peptide\_targeting drugs and Raynaud's phenomenon: a real\_world potential safety signal from the WHO pharmacovigilance database. J Headache Pain. 2022;23(1):53. • Gérard AO, Merino D, Drici MD. Real\_World Data on the Risk of Ventricular Arrhythmias with Sulfonamides. Clin Pharmacol Ther. 2022. • Gerard AO, Laurain A, Fresse A, Parassol N, Muzzone M, Rocher F, Esnault VLM, Drici MD. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database. Clin Pharmacol Ther. 2021;109(4):1021\_4. • Viard D, Gerard A, Tahiri J, Tieulie N, Van Obberghen E, Drici MD. Triptan overuse during pregnancy: a possible cause of placental hypoperfusion. Eur J Clin Pharmacol. 2021;77(2):269\_70. • Romani S, Gerard A, Fresse A, Viard D, Van Obberghen E, Micallef J, Rocher F, Drici MD. Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID\_19 Epidemic. Clin Transl Sci. 2021;14(1):163\_9. • Fresse A, Viard D, Romani S, Gerard A, Lepelletier M, Rocher F, Salem JE, Drici MD. Spontaneous reported cardiotoxicity induced by lopinavir/ritonavir in COVID\_19. An alleged past\_resolved problem. Int J Cardiol. 2021;324:255\_60. • Nguyen LS, Dolladille C, Drici MD, Fenioux C, Alexandre J, Mira JP et al. Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the WHO Pharmacovigilance Database. Circulation. 2020;142(3):303\_5. • Gerard A, Romani S, Fresse A, Viard D, Parassol N, Granvillemin A, Chouchana L, Rocher F, Drici MD. "Off\_label" use of hydroxychloroquine, azithromycin, lopinavir\_ritonavir and chloroquine in COVID\_19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. Therapie. 2020;75(4):371\_9. • Bernier M, Lancrerot SL, Parassol N, Lavrut T, Viotti J, Rocher F, Drici MD. Therapeutic Drug Monitoring of Direct Oral Anticoagulants May Increase Their Benefit\_Risk Ratio. J Cardiovasc Pharmacol. 2020; 76(4): 472\_7. • Bernier M, Lancrerot SL, Rocher F, Van Obberghen EK, Olivier P, Lavrut T, Parassol\_Girard N, Drici MD. Major bleeding events in octogenarians associated with drug interactions between dabigatran and P\_gp inhibitors. J Geriatr Cardiol. 2019;16(11):806\_11. • Quintard H, Viard D, Drici MD, Ruetsch C, Samama CM, Ichai C. Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding. Thromb Haemost. 2017;117(1):196\_7.

### Projects

### Memberships

IUPHAR : International Union of Pharmacology (US).

Fellow of the European Society of Cardiology (EU)  
Cardiac Muscle Society (US)  
Cardiac Rhythm Society (US)  
British Pharmacology Society (UK)  
French Society of Pharmacology and Therapeutics (FR)  
French Society of Cardiology (FR)  
French Society of Hypertension (FR)

#### Other Relevant Information